Buying Opportunity: 1 Great Stock That Is Down 11% in 2021

Kinaxis stock was among TSX’s high flyers in 2020. However, it lost momentum and tumbled in 2021. Still, it presents an excellent buying opportunity, as robust revenues should return in post-pandemic.

| More on:

The impact of natural calamities, extreme weather conditions, and other events on the supply chain pale compared to the 2020 health crisis. COVID-19 affected nearly all industries, not only a handful. Last year was a breakout year for Kinaxis (TSX:KXS), as it soared by as much as 119%.

The $4.36 billion provider of cloud-based subscription software for supply chain operations rewarded investors with a total return of 80.3%. However, the momentum fizzled out to start 2021. Kinaxis lost steam and eventually skidded 27.83% from its high of $218.56 on November 4, 2020. As of July 19, 2021, the tech stock trades at $157.52 — or a year-to-date loss of 11.05%.

There were profit takers, naturally, although the drastic pullback presents a buying opportunity. Market analysts recommend a strong buy rating for Kinaxis. Despite the tumble, they believe the growth runway is still very long. The leading fixer of supply chain issues can generate new businesses in 2021 and beyond to accelerate growth.

Q1 2021 highlights

The Q1 2021 (quarter ended March 31, 2021) wasn’t a rosy picture. While Kinaxis presented a 9% total revenue growth versus Q1 2020, it reported a US$1.53 million loss compared to the US$5.58 million profit in the same period last year. The notable highlights were the 19% and 16% growth in Software-as-a-Service (SaaS) revenue and adjusted EBITDA margin.

Nonetheless, John Sicard, president and CEO of Kinaxis, was pleased with the quarterly results. He said it was a good initial step towards achieving management’s outlook for 2021. While pandemic-related delays remain, the company expects to book new businesses. Sicard adds that apart from project expansions, the incremental subscription bookings were a new record.

Financial outlook

The advantage of Kinaxis is that its long-term contracts provide visibility into future contracted revenue. Management expects to realize between 17-20% growth in SaaS revenue in 2021. Its full-year revenue forecast is around US$242 to US$247 million. The adjusted EBITDA margin estimate is 11% to 14%.

Also, regarding unsatisfied or partially unsatisfied performance obligations, Kinaxis expects to recognize revenues of US$129.5 million and US$127 million in 2021 and 2022. The future amount for 2023 and later is around US$127.5 million. Meanwhile, the total backlog is about US$384 million.

Furthermore, management believes a 23-25% annual SaaS revenue growth beyond 2021 is achievable in the mid-term if business and market conditions return to normal or typical nature.

Robust revenues will return

Kinaxis has never been in the red for the past four years. It has averaged US$174.9 million and US$17.9 million in revenue and net income, respectively. Moreover, the company plays a vital role in the global supply chain. Business organizations in sectors such as technology, pharmaceuticals, industrial, consumer, and retail, among others, need agility to counter daily volatility.

Robust revenues and growing free cash flow should return in the post-pandemic following the disruption in 2020. Kinaxis has already succeeded in capturing the lion’s share of the market. It should maintain its industry-leading position once sales growth accelerates anew.

Kinaxis will capitalize on available opportunities as more companies upgrade their supply chain capabilities. Thus, the long-term prospects for the company remain very positive. Investors should take positions in this tech stock today or include it in their watchlists.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool recommends KINAXIS INC.

More on Tech Stocks

Canada Day fireworks over two Adirondack chairs on the wooden dock in Ontario, Canada
Tech Stocks

Best Tech Stocks for Canadian Investors in the New Year

Three tech stocks are the best options for Canadians investing in the high-growth sector.

Read more »

doctor uses telehealth
Tech Stocks

What to Know About Canadian Small-Cap Stocks for 2025

Small cap stocks are a great way to experience outsized gains. Here is what you need to know about small…

Read more »

A worker drinks out of a mug in an office.
Tech Stocks

A Top-Performing U.S. Stock That Canadian Investors Really Should Own

Canadian investors should buy and hold this top performing U.S. stock for generating significant returns in the long run.

Read more »

dividends grow over time
Tech Stocks

Got $1,500? 2 Tech Stocks to Buy and Hold Forever

Two tech stocks with high-growth potential are sound prospects for long-term investors.

Read more »

Soundhound AI is a leader in voice recognition software
Tech Stocks

3 Tech Stocks I’m Looking to Buy in January

From tech stocks with consistent growth histories to stocks experiencing a temporary bullish momentum, there are multiple attractive options in…

Read more »

The TFSA is a powerful savings vehicle for Canadians who are saving for retirement.
Tech Stocks

Take Full Advantage of Your TFSA: Growth Strategies for 2025

Maximize your TFSA in 2025 with proven growth strategies. Learn how to build a tax-free portfolio, avoid common mistakes, and…

Read more »

up arrow on wooden blocks
Tech Stocks

1 Soaring Stock I’d Buy Now With No Hesitation

Although it's from a rapidly evolving discipline and carries unique risks, the robotics stock's growth potential is too formidable and…

Read more »

Biotech stocks
Tech Stocks

Digital Healthcare Boom: 2 TSX Stocks Transforming Canadian Medicine

Even though telehealth stocks carry the risk factor of the tech sector and other innovative stocks, the profit margin can…

Read more »